Y-mAbs to Host Annual Research and Development Day in New York
December 06, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company today announced that it will host its...
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application
December 01, 2022 17:34 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 07, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022DANYELZA marketing authorization granted in Israel; regulatory filing...
Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022
November 02, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended...
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab
October 28, 2022 15:33 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Pivotal Data for Omburtamab
October 03, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
September 26, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab
September 01, 2022 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma
August 30, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the...
Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments
August 08, 2022 16:05 ET
|
Y-mAbs Therapeutics, Inc
Omburtamab BLA Accepted by the FDA with November 2022 PDUFA date Announced IND Clearance for the first GD2-SADA construct YTD DANYELZA® product revenue $20.3 millionManagement reiterates financial...